Loss of heterozygosity: What is it good for?

BMC Medical Genomics

Volumn 8, Issue 1, 2015, Pages

  Ryland, Georgina L ^a,b   Doyle, Maria A ^a   Goode, David ^a   Boyle, Samantha E ^a   Choong, David Y H ^a   Rowley, Simone M ^a   Li, Jason ^a   Bowtell, David Dl ^a   Tothill, Richard W ^a   Campbell, Ian G ^a,c   Gorringe, Kylie L ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Haploinsufficiency; Mutation; Ovarian cancer; SNP; Tumour suppressor gene

Indexed keywords

ANKRD32 GENE; APOOL GENE; ARTICLE; C9ORF172 GENE; CACNA1B GENE; CANCER SUSCEPTIBILITY; CASK GENE; CDH8 GENE; CDKN2A GENE; COHORT ANALYSIS; CONTROLLED STUDY; CYLC1 GENE; DACH2 GENE; DNAH9 GENE; EPHX2 GENE; EPIGENETICS; FANCA GENE; FARP1 GENE; FEMALE; GENE DISRUPTION; GENE DOSAGE; GENE EXPRESSION; GENE FREQUENCY; GENE INACTIVATION; GENE MUTATION; GENETIC SELECTION; GPR98 GENE; GRAMD4 GENE; HAPLOINSUFFICIENCY; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; IL16 GENE; LINGO1 GENE; MAJOR CLINICAL STUDY; MAP2K4 GENE; MEF2C GENE; MYOCD GENE; NF1 GENE; OVARY CANCER; PIK3R1 GENE; PNMA3 GENE; PRIORITY JOURNAL; PTEN GENE; RAI1 GENE; RB1 GENE; RPS6KA6 GENE; SAMD11 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SKG223 GENE; STARD5 GENE; SYNE1 GENE; TEX15 GENE; TP53 GENE; TUMOR SUPPRESSOR GENE; ZNF287 GENE; ZNRF4 GENE; GENETICS; GENOMICS; OVARY TUMOR; TUMOR GENE;

FEMALE; GENE DOSAGE; GENES, NEOPLASM; GENES, TUMOR SUPPRESSOR; GENOMICS; HAPLOINSUFFICIENCY; HUMANS; LOSS OF HETEROZYGOSITY; OVARIAN NEOPLASMS;

EID: 84938313385     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/s12920-015-0123-z     Document Type: Article

References (34)

1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-58. doi: 10.1126/science.1235122.
2. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature. 1983;305(5937):779-84.
3. Merajver SD, Frank TS, Xu J, Pham TM, Calzone KA, Bennett-Baker P, et al. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res. 1995;1(5):539-44.
4. Knudson Jr AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820-3.
5. Tomlinson IP, Lambros MB, Roylance RR. Loss of heterozygosity analysis: practically and conceptually flawed? Genes Chromosomes Cancer. 2002;34(4):349-53. doi: 10.1002/gcc.10085.
6. Gorringe KL, Ramakrishna M, Williams LH, Sridhar A, Boyle SE, Bearfoot JL, et al. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis. Genes Chromosomes Cancer. 2009;48(10):931-42.
7. Davis SJ, Choong DY, Ramakrishna M, Ryland GL, Campbell IG, Gorringe KL. Analysis of the mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer. BMC Cancer. 2011;11:173. doi: 10.1186/1471-2407-11-173.
8. Bryan EJ, Watson RH, Davis M, Hitchcock A, Foulkes WD, Campbell IG. Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and CYP2D, on chromosome 22q. Cancer Res. 1996;56(4):719-21.
9. Ryland GL, Bearfoot JL, Doyle MA, Boyle SE, Choong DY, Rowley SM, et al. MicroRNA genes and their target 3'-untranslated regions are infrequently somatically mutated in ovarian cancers. PLoS One. 2012;7(4):e35805. doi: 10.1371/journal.pone.0035805.
10. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-60. doi: 10.1093/bioinformatics/btp324.
11. Novocraft Technologies. http://www.novocraft.com.
12. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297-303. doi: 10.1101/gr.107524.110
13. Albers CA, Lunter G, Macarthur DG, McVean G, Ouwehand WH, Durbin R. Dindel: Accurate indel calls from short-read data. Genome Res. 2010. doi: 10.1101/gr.112326.110
14. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-6. doi: 10.1038/nbt.1754
15. Ramakrishna M, Williams LH, Boyle SE, Bearfoot JL, Sridhar A, Speed TP, et al. Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PLoS One. 2010;5(4), e9983. doi: 10.1371/journal.pone.0009983.
16. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463(7278):191-6. doi: 10.1038/nature08658.
17. Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding W, Koboldt DC, et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res. 2012;22(8):1589-98. doi: 10.1101/gr.134635.111.
18. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1):49-56. doi: 10.1002/path.2696.
19. McManus DT, Murphy M, Arthur K, Hamilton PW, Russell SE, Toner PG. p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma. J Pathol. 1996;179(2):177-82. doi: 10.1002/(SICI)1096-9896(199606)179:2<177::AID-PATH561>3.0.CO;2-2.
20. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-15. doi: 10.1038/nature10166.
21. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A. 2002;99(20):12963-8.
22. Davoli T, Xu AW, Mengwasser KE, Sack LM, Yoon JC, Park PJ, et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell. 2013;155(4):948-62. doi: 10.1016/j.cell.2013.10.011.
23. Cody NA, Ouellet V, Manderson EN, Quinn MC, Filali-Mouhim A, Tellis P, et al. Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene. 2007;26(4):618-32. doi: 10.1038/sj.onc.1209821.
24. Stronach EA, Sellar GC, Blenkiron C, Rabiasz GJ, Taylor KJ, Miller EP, et al. Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression. Cancer Res. 2003;63(24):8648-55.
25. England NL, Cuthbert AP, Trott DA, Jezzard S, Nobori T, Carson DA, et al. Identification of human tumour suppressor genes by monochromosome transfer: rapid growth-arrest response mapped to 9p21 is mediated solely by the cyclin-D-dependent kinase inhibitor gene, CDKN2A (p16INK4A). Carcinogenesis. 1996;17(8):1567-75.
26. Murakami Y. Functional cloning of a tumor suppressor gene, TSLC1, in human non-small cell lung cancer. Oncogene. 2002;21(45):6936-48. doi: 10.1038/sj.onc.1205825.
27. Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res. 1998;4(10):2433-7.
28. Earp MA, Kelemen LE, Magliocco AM, Swenerton KD, Chenevix-Trench G, Australian Cancer S, et al. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet. 2014;133(5):481-97. doi: 10.1007/s00439-013-1383-3.
29. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 2013;45(4):362-70. doi: 10.1038/ng.2564.70e1-2.
30. International HapMap C. The International HapMap Project. Nature. 2003;426(6968):789-96. doi: 10.1038/nature02168.
31. Presneau N, Manderson EN, Tonin PN. The quest for a tumor suppressor gene phenotype. Curr Mol Med. 2003;3(7):605-29.
32. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4(3):177-83. doi: 10.1038/nrc1299.
33. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-15. doi: 10.1038/nature10166
34. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2012;2(5):401-4. doi: 10.1158/2159-8290.CD-12-0095